Skip to content
Home/Companies/Biotech/Edgewise Therapeutics

Edgewise Therapeutics

Biotech·United States·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Edgewise Therapeutics?

Edgewise Therapeutics is an American Biotech company, currently owned by Novo Holdings since 2019.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Novo Holdings
Investor
Novo Holdings
Novo Holdings Venture Investments · 1999 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Novo Holdings Venture Investments

Other portfolio companies in the same fund.

Claris Biotherapeutics
Active
BiotechUS· 2026
Windward Bio AG
Active
BiotechSwitzerland· 2026
AnaCardio
Active
BiotechSweden· 2025
Expedition Therapeutics
Active
BiotechUS· 2025
KIVU Bioscience
Active
BiotechUS· 2025
Asceneuron
Active
BiotechSwitzerland· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Edgewise Therapeutics?

Edgewise Therapeutics is currently owned by Novo Holdings, through Novo Holdings Venture Investments, since 2019.

When did Novo Holdings acquire Edgewise Therapeutics?

Novo Holdings acquired Edgewise Therapeutics in 2019.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue